THE GENERATION OF AN EML4-ALK FUSION NSCLC ISOGENIC CELL LINE RELEVANT FOR DRUG DISCOVERY AND DEVELOPMENT

Metewo Selase Enuameh, PhD, Lysa-Anne Volpe, Michael Jackson, John Foulke, Luping Chen, Brian Shapiro, PhD, and Fang Tian, PhD

ABSTRACT
Gene editing tools such as CRISPR/Cas9 can be used to create isogenic cell lines, which can be further used to model a specific patient population for identifying novel, personalized treatment regimens. An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene, a key oncogenic driver, and then tested for its sensitivity to known selective inhibitors of ALK.

INTRODUCTION
The ALK gene regulates cell growth and plays an essential role in the development of the brain by helping with the proliferation of nerve cells.¹ When ALK acquires gene-specific mutations, forms a fusion gene with other genes, or gains additional gene copies, it becomes oncogenic. This ALK genetic abnormality is a key oncogenic driver, especially in non-small cell lung cancer (NSCLC), accounting for 3–7% of NSCLC cases observed in the United States.² -⁴ Recent studies show that tumor cells derived from a subset of patients with NSCLC harbor the EML4-ALK fusion oncogene, which is the result of a paracentric chromosomal inversion on the short arm of chromosome 2. The EML4-ALK oncogene, like other ALK fusion oncogenes, is a druggable target that is responsive to ALK inhibitors. However, there is a lack of EML4-ALK in vitro models for drug screening. Here, we set out to generate an isogenic EML4-ALK fusion non-small cell lung cancer model in the A549 lung cancer cell line (ATCC® CCL-185IG™), which harbors other naturally occurring genomic aberrations inherent in non-small cell lung cancer. This model could serve as a clinically relevant drug screening cell model.⁵ ,⁶

RESULTS AND DISCUSSION
GENE EDITING WITH CRISPR/CAS9
We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung cancer cell line. Single guide RNAs (sgRNAs) designed and built to guide Cas9 to bind and cut desired intronic regions in the EML4 and ALK gene targets, trigger the paracentric genomic rearrangement event upon co-transfection (Figure 1).
**GENOTYPE OF EML4-ALK MUTATED CELL LINE**

The introduction of the EML4-ALK mutation in the cell line was confirmed via Sanger sequencing as shown in Figure 2 (A, B) for the expected 5p and 3p genomic breakpoints. Sanger sequencing of prepared EML4-ALK cDNA from mRNA of the mutated cell line was carried out to confirm the expression of the EML4-ALK fusion transcript (Figure 2C). We subsequently confirmed expression of the EML4-ALK fusion protein to be an 86 kDa fragment as expected by western blotting (data not shown).
FUNCTIONAL CHARACTERIZATION OF EML4-ALK MUTATED CELL LINES

Functional testing of the isogenic A549 EML4-ALK cell line gave a favorable drug response in comparison to its parental A549 cell line (Figure 3). Dose response curves for cells treated with ALK inhibitors crizotinib and ceritinib (Figure 3 A, B) showed that the isogenic A549 EML4-ALK cell line has selective drug sensitivity to ALK inhibitors crizotinib and ceritinib relative to the parental A549 cell line. Furthermore, this trend is consistent irrespective of whether it is a dose-response based assay monitored via IncuCyte FLR® live cell imaging system (Essen BioScience; Figure 3 A, B) or the CellTiter-Glo® Luminiscent Cell Viability Assay (Promega; Figure 3 C, D).

![Crizotinib dose-response](#)

<table>
<thead>
<tr>
<th>Survival rate (%)</th>
<th>-7</th>
<th>-6</th>
<th>-5</th>
</tr>
</thead>
<tbody>
<tr>
<td>A549 - Crizotinib</td>
<td>120</td>
<td>100</td>
<td>80</td>
</tr>
<tr>
<td>CCL-185IG - Crizotinib</td>
<td>100</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>IC50</td>
<td>1.482e-006</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

![Ceritinib dose-response](#)

<table>
<thead>
<tr>
<th>Survival rate (%)</th>
<th>-6.5</th>
<th>-6.0</th>
<th>-5.5</th>
<th>-5.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>A549 - Ceritinib</td>
<td>120</td>
<td>100</td>
<td>80</td>
<td>60</td>
</tr>
<tr>
<td>CCL-185IG - Ceritinib</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
</tr>
<tr>
<td>IC50</td>
<td>2.139e-006</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 3: CCL-185IG is sensitive to ALK inhibitor drugs.** (A, B) A549 and CCL-185IG cells were treated with the indicated concentrations of ALK inhibitors crizotinib and ceritinib and cell survival was determined via live cell analysis. (C, D) A549 and CCL-185IG cells were treated with 1 µM of same compounds and cell survival was confirmed by CellTiter-Glo Luminescent Cell Viability Assay.

CONCLUSION

In this study, we utilized the CRISPR/Cas9 genome editing platform to target endogenous loci in human cells and create the intended genomic translocation event. By employing sgRNA-Cas9 constructs designed to cut precisely at relevant translocation breakpoints, we induced cancer-relevant genomic rearrangements that resulted in the expression of EML4–ALK gene fusion products. Breakpoint junction analysis tested after sgRNA-CRISPR/Cas9-mediated genomic DNA cleavage in A549 cells revealed the successful creation of the EML4-ALK fusion found in tumor cells from a subpopulation of NSCLC patients. Furthermore, single clonal isolation and functional screening demonstrated that the EML4-ALK isogenic cell line (CCL-185IG) was sensitive to ALK inhibitors relative to the parental A549 cell line. This newly developed EML4-ALK isogenic lung cancer cell line is a useful model to study the tyrosine kinase signaling pathway and to screen for novel ALK inhibitors in anti-cancer drug discovery and development.
REFERENCES


